SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The principal diagnosis/indication for this assessment is chronic diarrhoea due to bile acid malabsorption (BAM). Diarrhoea can be defined as the abnormal passage of loose or liquid stools more than three times daily and/or a daily stool weight > 200 g per day and is considered to be chronic if it persists for more than 4 weeks. The cause of chronic diarrhoea in adults is often difficult to ascertain and patients may undergo several investigations without a definitive cause being identified. BAM is one of several causes of chronic diarrhoea and results from failure to absorb bile acids (which are required for the absorption of dietary fats and sterols in the intestine) in the distal ileum. OBJECTIVE: For people with chronic diarrhoea with unknown cause and in people with Crohn's disease and chronic diarrhoea with unknown cause (i.e. before resection): (1) What are the effects of selenium-75-homocholic acid taurine (SeHCAT) compared with no SeHCAT in terms of chronic diarrhoea, other health outcomes and costs? (2) What are the effects of bile acid sequestrants (BASs) compared with no BASs in people with a positive or negative SeHCAT test? (3) Does a positive or negative SeHCAT test predict improvement in terms of chronic diarrhoea, other health outcomes and costs? DATA SOURCES: A systematic review was conducted to summarise the evidence on the clinical effectiveness of SeHCAT for the assessment of BAM and the measurement of bile acid pool loss. Search strategies were based on target condition and intervention, as recommended in the Centre for Reviews and Dissemination (CRD) guidance for undertaking reviews in health care and the Cochrane Handbook for Diagnostic Test Accuracy Reviews. The following databases were searched up to April 2012: MEDLINE; MEDLINE In-Process & Other Non-Indexed Citations; EMBASE; the Cochrane Databases; Database of Abstracts of Reviews of Effects; Health Technology Assessment (HTA) Database; and Science Citation Index. Research registers and conference proceedings were also searched. REVIEW METHODS: Systematic review methods followed the principles outlined in the CRD guidance for undertaking reviews in health care and the National Institute for Health and Care Excellence (NICE) Diagnostic Assessment Programme interim methods statement. In the health economic analysis, the cost-effectiveness of SeHCAT for the assessment of BAM, in patients with chronic diarrhoea, was estimated in two different populations. The first is the population of patients with chronic diarrhoea with unknown cause and symptoms suggestive of diarrhoea-predominant irritable bowel syndrome (IBS-D) and the second population concerns patients with Crohn's disease without ileal resection with chronic diarrhoea. For each population, three models were combined: (1) a short-term decision tree that models the diagnostic pathway and initial response to treatment (first 6 months); (2) a long-term Markov model that estimates the lifetime costs and effects for patients initially receiving BAS; and (3) a long-term Markov model that estimates the lifetime costs and effects for patients initially receiving regular treatment (IBS-D treatment in the first population and Crohn's treatment in the second population). Incremental cost-effectiveness ratios were estimated as additional cost per additional responder in the short term (first 6 months) and per additional quality-adjusted life-year (QALY) in the long term (lifetime). RESULTS: We found three studies assessing the relationship between the SeHCAT test and response to treatment with cholestyramine. However, the studies had small numbers of patients with unknown cause chronic diarrhoea, and they used different cut-offs to define BAM. For the short term (first 6 months), when trial of treatment is not considered as a comparator, the optimal choice depends on the willingness to pay for an additional responder. For lower values (between £1500 and £4600) the choice will be no SeHCAT in all scenarios; for higher values either SeHCAT 10% or SeHCAT 15% becomes cost-effective. For the lifetime perspective, the various scenarios showed widely differing results: in the threshold range of £20,000-30,000 per QALY gained we found as optimal choice either no SeHCAT, SeHCAT 5% (only IBS-D) or SeHCAT 15%. When trial of treatment is considered a comparator, the analysis showed that for the short term, trial of treatment is the optimal choice across a range of scenarios. For the lifetime perspective with trial of treatment, again the various scenarios show widely differing results. Depending on the scenario, in the threshold range of £20,000-30,000 per QALY gained, we found as optimal choice either trial of treatment, no SeHCAT or SeHCAT 15%. CONCLUSIONS: In conclusion, the various analyses show that for both populations considerable decision uncertainty exists and that no firm conclusions can be formulated about which strategy is optimal. Standardisation of the definition of a posit
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Deeks, J. J., Macaskill, P., & Irwig, L. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.01.016 · Cited by 2,910
WEDLAKE, L., A’HERN, R., RUSSELL, D., THOMAS, K., WALTERS, J. R. F., & ANDREYEV, H. J. N. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04081.x · Cited by 435
The Irritable Bowel Syndrome: Long-Term Prognosis and the Physician-Patient Interaction
Owens, D. M., Nelson, D. K., & Talley, N. J. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-2-199501150-00005 · Cited by 349
A systematic review classifies sources of bias and variation in diagnostic test accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., & Mallett, S. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.05.014 · Cited by 283
An Evidence Based Checklist for the Peer Review of Electronic Search Strategies (PRESS EBC)
McGowan, J., Sampson, M., & Lefebvre, C. (2010) · Evidence Based Library and Information Practice · doi:10.18438/b8sg8r · Cited by 200
Camilleri, M., Nadeau, A., Tremaine, W. J., Lamsam, J., Burton, D., Odunsi, S., Sweetser, S., & Singh, R. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01288.x · Cited by 153
Limited search strategies were effective in finding relevant nonrandomized studies
Furlan, A. D., Irvin, E., & Bombardier, C. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.03.004 · Cited by 54
Bile acid malabsoption: a forgotten diagnosis?
Khalid, U., Lalji, A., Stafferton, R., & Andreyev, J. (2010) · Clinical Medicine · doi:10.7861/clinmedicine.10-2-124 · Cited by 53
Reporting of article retractions in bibliographic databases and online journals.
Wright, K., & McDaid, C. (2011) · Journal of the Medical Library Association : JMLA · doi:10.3163/1536-5050.99.2.010 · Cited by 48
Cited by
Arasaradnam, R. P., Brown, S., Forbes, A., Fox, M. R., Hungin, P., Kelman, L., Major, G., O’Connor, M., Sanders, D. S., Sinha, R., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315909 · Cited by 332
Slattery, S. A., Niaz, O., Aziz, Q., Ford, A. C., & Farmer, A. D. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13227 · Cited by 214
“the diagnostic accuracy of SeHCAT has only been evaluated by response to treatment with bile acid sequestrants, and therefore maybe liable to assessment bias due to lack of blinding both in investigators and patients.(46) Further-”
MethodEffect of Increased Bile Acid Synthesis or Fecal Excretion in Irritable Bowel Syndrome-Diarrhea
Camilleri, M., Busciglio, I., Acosta, A., Shin, A., Carlson, P., Burton, D., Ryks, M., Rhoten, D., Lamsam, J., Lueke, A., et al. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.215 · Cited by 114
Metadata
- Authors
- Riemsma, R., Al, M., Corro Ramos, I., Deshpande, S., Armstrong, N., Lee, Y.-C., Ryder, S., Noake, C., Krol, M., Oppe, M., Kleijnen, J., & Severens, H.
- Venue
- Health Technology Assessment
- Published
- 2013-12
- Volume
- 17
- Issue
- 61
- Pages
- 1-236
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2052082457
- Cited by
- 47
- References
- 11
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.